Opportunities and challenges in cell and gene therapy development

Cell and Gene Therapy: Q&A with Dr. Ger Brophy, Executive Vice President, Biopharma Production

One of the most revolutionary trends driving the biopharmaceutical sector is cell and genetic therapies. According to material in The Journal of Gene Medicine, as of November 2017 nearly 2,600 gene therapy clinical trials have been undertaken in 38 countries around the world.

In a recent interview, Ger Brophy gave his perspective on this growing segment of the bioprocessing industry as he discussed several key trends and challenges.

Is the excitement about cell and gene therapy justified

I think it’s a very exciting space, and we’re seeing the number of trials grow. It’s probably most exciting because of the technology’s ability to impact patients’ lives. Yes, the numbers of patients are relatively small at this point in time. This is partly because biopharma researchers and manufacturers wanted to deal with small populations that they understood well and, in many cases, that didn’t really have many other options for treatments.

We’re seeing these companies moving on now to larger populations — starting with leukemia, now lymphomas. From our perspective, the key is multiple myeloma. If those patients begin to see benefits from cell and gene therapies, I think the excitement will feel justified.

Why is cell and gene therapy considered such a game-changer for the biopharma industry?

The game-changer here is that you are using the body’s own systems, either from a cellular immune system or from the ability to repair and replace defective or missing genes. We’re seeing the patient’s own immune system used to fight cancers. CAR-T cell therapy is arguably among the most personalized medicine one can consider. The patient’s own T cells are extracted, modified, activated, expanded, purified and returned to the patient.

Among the first patients treated for acute lymphoblastic leukemia, several are alive and thriving — four, five, six years later. We’re actually beginning to see real, tangible effects from the molecular knowledge now that we have an understanding of how the disease develops and how the patient responds to it.

Tell us about the industry — what kind of companies are working today in cell and gene therapy and what are some of their major challenges?

Many of the early movers in cell and gene therapy were small biotech startups. Increasingly, we’ve all seen a greater interest by the major biopharma industry. Novartis was probably the biggest; it started the earliest, and was successful in getting approval for Kymriah. As companies of this size get involved, we expect they will leverage their increased breadth and depth to develop new labels, develop new trials, and find ways to manufacture these therapies at scale.

And two of the most critical challenges are scalability and manufacturability. If we can manufacture these treatments at scale, can we do so safely? Can we do so at a reasonable cost so the populations that are affected by these diseases can access treatments?

Variables and failure modes have to be taken out of the process. If we can improve technologies like sterile fluid transfer, use excipient technology to further stabilize these technologies and use analytical technology to understand what will make a successful or less successful therapy, we can increase the efficacy, decrease the risk and decrease the cost.

This is where Avantor can help, since we supply cell-culture components, production chemicals and single-use technologies that aid in these processes. I think our knowledge — of cell culture, of technology development, sterile fluid transfer, fill and finish and excipients and the technology surrounding those — will be valuable and applicable to helping make these technologies available at scale.

Download the full article to continue reading the interview

Dr. Brophy discusses other key issues facing cell and gene therapy development, including:

  • What tools do companies need to solve standardization challenges?
  • How can we reduce the risk factors and side effects associated with this therapy?
  • Are regulators supportive of this therapy, or are they hindering its growth?

Read more insights on gene therapy

Dr. Ger Brophy

Executive Vice President, Biopharma Production

Dr. Ger Brophy is Executive Vice President, Biopharma Production at Avantor. In his current role, he is responsible for developing and implementing Avantor’s Biopharma Production offering to support current and future customer needs. Prior to joining Avantor, Dr. Brophy held a variety of research and development, strategy, advanced systems, and business development positions with GE Healthcare Life Sciences, GE Healthcare Medical Diagnostics and Amersham for nearly 30 years. Dr. Brophy earned a Bachelor of Science in biotechnology, as well as a doctorate in molecular biology from Dublin City University in Ireland.

Solutions for bioprocessing

From the small-scale bench to full commercial manufacturing, we enable our customers to reach the market with new treatments for patients, faster and safer. Learn more about our offering for biopharmaceutical manufacturing.

Customer support

Contact us

Ready to streamline your bioprocessing manufacturing workflows? Avantor Biopharma Production can help.

Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 300,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world.